Premium
Caveolin and the aged myocardium
Author(s) -
Kidd Michael W.,
Reichelt Melissa E.,
Peart Jason N.,
Niesman Ingrid R.,
Head Brian P.,
Headrick John,
Roth David M.,
Patel Hemal H.
Publication year - 2010
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.24.1_supplement.819.2
Subject(s) - medicine , cardiology , diastole , caveolin 1 , blood pressure
The aged heart is more susceptible to ischemic injury than the young heart. We hypothesized that loss of efficiency via reduced cellular scaffolds leads to this susceptibility. We examined the contribution of caveolin‐3 (Cav‐3), a lipid‐raft scaffolding protein, to ischemic tolerance in aged myocardium. Cav‐3 expression was reduced in aged hearts. Cardiac‐specific expression of Cav‐3 improved ischemic tolerance in both young (3 months) and aged (24 months) hearts. Aged WT hearts exhibited significant dysfunction, recovering only 20–25% of force and exhibiting almost 2‐fold higher diastolic pressure. Overexpression of Cav‐3 profoundly improved outcome in aged hearts with 60–65% recovery of pressure development and end diastolic pressure in the normal range. These data reveal a parallel decline in cardiac ischemic tolerance and Cav‐3 expression, and indicate that increasing Cav‐3 expression can eliminate age‐related ischemic intolerance. Cav‐3 may serve as a novel therapeutic target to limit dysfunction associated with cardiac aging.